Advice
Recommended for restricted use within NHS Scotland.
REASONS FOR ADVICE
Capecitabine is recommended for use in Scotland by oncologists with appropriate expertise in treating locally advanced/metastatic breast cancer. It is an orally active treatment which has improved outcomes both as monotherapy in those previously treated with an anthracycline and a taxane, and in combination with docetaxel in those previously treated with an anthracycline.
Download detailed advice22KB (PDF)
Medicine details
- Medicine name:
- Capecitabine (Xeloda®)
- SMC ID:
- 34/03
- Indication:
- Metastatic breast cancer
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 07 March 2003